Cyclin A/B RxL macrocyclic inhibitors to treat cancers with high E2F activity

Cancer cell proliferation requires precise control of E2F1 activity; excess activity promotes apoptosis. Here, we developed cell-permeable and bioavailable macrocycles that selectively kill small cell lung cancer (SCLC) cells with inherent high E2F1 activity by blocking RxL-mediated interactions of...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Singh, S, Gleason, CE, Fang, M, Laimon, YN, Khivansara, V, Xie, S, Durmaz, YT, Sarkar, A, Ngo, K, Savla, V, Li, Y, Abu-Remaileh, M, Li, X, Tuladhar, B, Odeh, R, Hamkins-Indik, F, He, D, Membreno, MW, Nosrati, M, Gushwa, NN, Leung, SSF, Fraga-Walton, B, Hernandez, L, Baldomero, MP, Lent, BM, Spellmeyer, D, Luna, JF, Hoang, D, Gritsenko, Y, Chand, M, DeMart, MK, Metobo, S, Bhatt, C, Shapiro, JA, Yang, K, Dupper, NJ, Bockus, AT, Doench, JG, Aggen, JB, Liu, L-F, Levin, B, Wang, EW, Vendrell, I, Fischer, R, Kessler, B, Gokhale, PC, Signoretti, S, Spektor, A, Kreatsoulas, C, Singh, R, Earp, DJ, Garcia, PD, Nijhawan, D, Oser, MG
التنسيق:	Internet publication
اللغة:	English
منشور في:	2024

Cyclin A/B RxL macrocyclic inhibitors to treat cancers with high E2F activity

مواد مشابهة